Engineered “living drugs” take aim at aging

Background

As populations worldwide grow older, age-related disorders—from Alzheimer's disease and atherosclerosis to osteoarthritis and pulmonary fibrosis—are placing mounting pressure on health systems. A new review argues that a therapy best known for treating blood cancers may hold a key: chimeric antigen receptor (CAR) T cells, engineered “living drugs” that can be redirected to seek out and destroy senescent cells.

Senescent cells irreversibly stop dividing, yet resist apoptosis and remain metabolically active. They release a potent mixture of pro-inflammatory cytokines, chemokines, matrix-degrading enzymes, and growth factors termed the senescence-associated secretory phenotype (SASP), fueling “inflammaging” and fibrosis across organs. Two core cell-cycle pathways—p53–p21 and p16–Rb—govern the arrest.

First-generation senolytics (e.g., navitoclax; dasatinib plus quercetin) and senomorphics have shown promise but are limited by modest specificity, uneven tissue distribution, poor blood–brain barrier penetration, transient effects from intermittent dosing, off-target toxicity, or the need for chronic treatment. CAR-T cells, by contrast, offer long-term persistence, in vivo expansion, and precise, antigen-directed killing.

Key advances

1. Molecular map and disease links

The review first details the hallmarks of senescent cells—cell-cycle arrest, SASP, and defective mitochondria, lysosomes, and endoplasmic reticulum (Fig. 1)—and then traces how these cells drive pathology across the brain, heart, lungs, liver, kidneys, and vasculature (Fig. 2), establishing a shared node for multi-disease intervention.

2. Engineering CAR-T cells for senescence

A modular CAR combines an extracellular scFv, hinge, transmembrane domain, costimulatory domain, and CD3ζ. Programmable strategies—AND/OR/NOT logic gates, iCasp9 safety switches, light- and ultrasound-controlled platforms, and CRISPR-based universal cells—enable the move from tumor to senescence targets. Candidate antigens include uPAR, NKG2D, FAP, PDGFR, and CCR2 (Fig. 3).

3. From clearance to repair: preclinical evidence

For uPAR, single-cell data show over 60% co-expression with p16. uPAR CAR-T cells reduced senescent cells by 87% and collagen deposition by 52% in liver fibrosis models, improved metabolic function and exercise capacity, and extended lifespan in aged mice after a single dose; a humanized PL40 mRNA-encoded uPAR CAR has also been developed.

For NKG2D, ligands such as MICA roughly double on senescent cells, while Nkg2d-knockout mice showed a 50% increase in fibrotic area and 45% greater senescent-cell accumulation. NKG2D CAR-T cells cleared senescent cells induced by diverse stressors with little effect on normal cells. FAP and PDGFRβ CAR-T cells likewise reduced collagen and improved cardiac ejection fraction and renal function—demonstrating a dual “clearance–repair” effect.

4. Comparative edge and trade-offs

Compared with senolytics, senomorphics, and stem cell therapy, CAR-T offers higher specificity and durable, single-infusion potential. The authors note real trade-offs: complex and costly individualized manufacturing, and risks of cytokine release syndrome, neurotoxicity, and on-target/off-tumor toxicity.

5. Challenges and safeguards

Because senescent cells also serve physiological roles in repair, development, and immune regulation, synNotch AND gates and triple AND gates are proposed to limit on-target/off-tumor activity. iCasp9 and HSVTK suicide genes, together with drug-, light-, and ultrasound-controlled switches, provide rapid safety overrides. For aged donors, thymic involution and shortened telomeres are addressed by selecting high-quality naive cells (CD45RA+CCR7+CD62L+), IL-15/IL-7-based culture (66% more CD4+ CAR-T cells, 133% more stem-cell memory T cells, 40% fewer exhaustion markers), low-dose rapamycin, and TERT mRNA electroporation (about 0.9 kb telomere extension; 43 population doublings). Humanized mice and nonhuman primates are recommended for efficacy and long-term safety assessment (Fig. 4).

Significance

The work frames a shift from treating single diseases to intervening in shared aging processes. The authors stress that all anti-senescence CAR-T research remains preclinical and has not been approved by any regulatory authority; safety and controllability must take precedence.

Outlook

mRNA–lipid nanoparticle delivery could generate transient CAR-T cells directly in vivo, making the therapy more drug-like and accessible. Artificial intelligence and machine learning—graph neural networks, Transformer models, and platforms such as CAR-Toner—can predict antigen combinations, CAR architecture, logic circuits, and safety switches. Advanced CARs secreting SASP-neutralizing nanobodies achieved up to 45% less collagen and 70%–80% lower serum SASP in preclinical models. Sequential senolytic-then-CAR-T treatment offers temporal synergy, while indications such as idiopathic pulmonary fibrosis, with endpoints centered on functional improvement and quality of life, may lead early translation. Deep collaboration across aging biology, immunology, and genetic engineering will be essential to realize healthy aging.

Sources: https://spj.science.org/doi/10.34133/research.1326